$IBRX A remainder: The FDA approved ANKTIVA in combination with BCG on April 22,2024. Papillary NMIBC label expansion. Lymphopenia and Pancreatic cancer, both have RMAT designations since February 2025. A guaranteed spot in one of the Russell 3000 and Russell 2000 on June 26. Dr. Patrick’s big announcement next month. Probably a an early earnings report. Global expansion, the EU (Portugal & Greece), UK, Japan, Saudi Arabia, Macau, India, South Africa, etc. ANKTIVA will cure other cancers such as Glioblastoma, Prostate, Neck, Colon, Liver, Breast, Lung. A strong pipeline. Long Covid. Infections like HIV and Sepsis. Lynch syndrome (Cancer prevention vaccine). No chemotherapy. World Bank of NK cells and the immune cells manufactured by Al robots. Next generation of CAR-T therapy for leukemi
在 X 查看 ↗